EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization

Teodorikez-Wilfox Jimenez-Rodriguez iD, Leticia de Las Vecillas iD, Marina Labella iD, Donna-Marie Lynch, Kylie Marie Besz, Kathleen Marquis, Amparo Burgos, Victor Soriano Gomis, Inmaculada Lozano, Rosa Ana Montoyo Antón, Francisco Marco de la Calle, María Purificación González Delgado und 5 weitere

Allergy · 2024

DOI: 10.1111/all.15940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2024. Verfasst von Teodorikez-Wilfox Jimenez-Rodriguez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Hypersensitivity, Hypersensitivity. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug hypersensitivity reactions (DHRs) to platinum‐based drugs are heterogenous and restrict their access, and drug desensitization (DD) has provided a ground‐breaking procedure for their re‐introduction, although the response is heterogeneous. We aimed to identify the phenotypes, endotypes, and biomarkers of reactions to carboplatin and oxaliplatin and their response to DD.

Methods

Seventy‐nine patients presenting with DHRs to oxaliplatin ( N = 46) and carboplatin ( N = 33) were evaluated at the Allergy Departments of two tertiary care hospitals in Spain. Patient symptoms, skin testing, biomarkers, and outcomes of 267 DDs were retrospectively analyzed.

Results

Oxaliplatin‐reactive patients presented with type I (74%), cytokine release reaction (CRR) (11%), and mixed (Mx) (15%) phenotypes. In contrast, carboplatin reactive patients presented with predominantly type I (85%) and Mx (15%) but no CRRs. Out of 267 DDs, breakthrough reactions (BTRs) to oxaliplatin occurred twice as frequently as carboplatin (32% vs. 15%; p < .05). Phenotype switching from type I to another phenotype was observed in 46% of oxaliplatin DDs compared to 21% of carboplatin DDs. Tryptase was elevated in type I and Mx reactions, and IL‐6 in CRR and Mx, indicating different mechanisms and endotypes.

Conclusion

Carboplatin and oxaliplatin induced three different types of reactions with defined phenotypes and endotypes amendable to DD. Although most of the initial reactions for both were type I, oxaliplatin presented with unique CRR reactions. During DD, carboplatin reactive patients presented mostly type I BTR, while oxaliplatin‐reactive patients frequently switched from type I to CRR, providing a critical difference and the need for personalized DD protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug HypersensitivityHypersensitivityHumansOxaliplatinCarboplatinRetrospective StudiesDesensitization, ImmunologicCytokinesPhenotypeBiomarkers

Stichwörter der Autor:innen

carboplatindesensitizationendophenotypehypersensitivityoxaliplatin

Substanzen

OxaliplatinCarboplatinAntineoplastic AgentsCytokinesBiomarkers

Autor:innen und Institutionen

  • Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.
  • Allergy Section, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
  • Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.
  • Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.

ORCID-Profile: Teodorikez-Wilfox Jimenez-Rodriguez, Leticia de Las Vecillas, Marina Labella

Zitieren

APA

Jimenez-Rodriguez, T. W., de Las Vecillas, L., Labella, M., Lynch, D. M., Besz, K. M., Marquis, K., Burgos, A., Soriano Gomis, V., Lozano, I., Antón, R. A. M., de la Calle, F. M., González Delgado, M. P., Gutiérrez, A., Montenegro, E., Rodríguez, F., Fernández Sánchez, F. J., & Castells, M. (2024). Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization. Allergy. https://doi.org/10.1111/all.15940

Vancouver

Jimenez-Rodriguez TW, de Las Vecillas L, Labella M, Lynch DM, Besz KM, Marquis K, et al. Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization. Allergy. 2024. doi:10.1111/all.15940

BibTeX
@article{JimenezRodriguez2024,
  author = {Jimenez-Rodriguez, Teodorikez-Wilfox and de Las Vecillas, Leticia and Labella, Marina and Lynch, Donna-Marie and Besz, Kylie Marie and Marquis, Kathleen and Burgos, Amparo and Soriano Gomis, Victor and Lozano, Inmaculada and Antón, Rosa Ana Montoyo and de la Calle, Francisco Marco and González Delgado, María Purificación and Gutiérrez, Aurora and Montenegro, Estefanía and Rodríguez, Fernando and Fernández Sánchez, Francisco Javier and Castells, Mariana},
  title = {Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15940}
}
Kostenlos starten →